These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 12658893)

  • 21. Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy.
    Giaccone G; Iacona RB; Fandi A; Janas M; Ochs JS; Herbst RS; Johnson DH
    J Cancer Res Clin Oncol; 2009 Mar; 135(3):467-76. PubMed ID: 18787840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer.
    Pernas FG; Allen CT; Winters ME; Yan B; Friedman J; Dabir B; Saigal K; Mundinger GS; Xu X; Morris JC; Calvo KR; Van Waes C; Chen Z
    Clin Cancer Res; 2009 Apr; 15(7):2361-72. PubMed ID: 19318490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gefitinib (Iressa): a novel treatment for non-small cell lung cancer.
    Vansteenkiste J
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):5-17. PubMed ID: 14748652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know.
    Raben D; Helfrich B; Ciardiello F; Bunn PA
    Lung Cancer; 2003 Aug; 41 Suppl 1():S15-22. PubMed ID: 12867058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The rational basis of using novel targeted biological agents in non-small cell lung cancer.
    Ciardiello F
    Suppl Tumori; 2002; 1(4):S31-3. PubMed ID: 12415813
    [No Abstract]   [Full Text] [Related]  

  • 26. β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells.
    Fang X; Gu P; Zhou C; Liang A; Ren S; Liu F; Zeng Y; Wu Y; Zhao Y; Huang B; Zhang Z; Yi X
    Pulm Pharmacol Ther; 2014 Jun; 28(1):41-48. PubMed ID: 23707949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
    Miller VA; Johnson DH; Krug LM; Pizzo B; Tyson L; Perez W; Krozely P; Sandler A; Carbone D; Heelan RT; Kris MG; Smith R; Ochs J
    J Clin Oncol; 2003 Jun; 21(11):2094-100. PubMed ID: 12775734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.
    Price N; Belani C
    Clin Lung Cancer; 2005 Jan; 6(4):214-6. PubMed ID: 15694012
    [No Abstract]   [Full Text] [Related]  

  • 29. Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention?
    Konecny GE; Wilson CA; Slamon DJ
    J Natl Cancer Inst; 2003 Dec; 95(24):1813-5. PubMed ID: 14679144
    [No Abstract]   [Full Text] [Related]  

  • 30. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
    Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
    Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer.
    Parra HS; Cavina R; Latteri F; Zucali PA; Campagnoli E; Morenghi E; Grimaldi GC; Roncalli M; Santoro A
    Br J Cancer; 2004 Jul; 91(2):208-12. PubMed ID: 15187994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
    Sugawara S; Oizumi S; Minato K; Harada T; Inoue A; Fujita Y; Maemondo M; Yoshizawa H; Ito K; Gemma A; Nishitsuji M; Harada M; Isobe H; Kinoshita I; Morita S; Kobayashi K; Hagiwara K; Kurihara M; Nukiwa T
    Ann Oncol; 2015 May; 26(5):888-894. PubMed ID: 25669832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tyrosine kinase inhibitors-ZD1839 (Iressa).
    Arteaga CL; Johnson DH
    Curr Opin Oncol; 2001 Nov; 13(6):491-8. PubMed ID: 11673690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel EGFR inhibitor suppresses survivin expression and tumor growth in human gefitinib-resistant EGFR-wild type and -T790M non-small cell lung cancer.
    Wang SP; Hsu YP; Chang CJ; Chan YC; Chen CH; Wang RH; Liu KK; Pan PY; Wu YH; Yang CM; Chen C; Yang JM; Liang MC; Wong KK; Chao JI
    Biochem Pharmacol; 2021 Nov; 193():114792. PubMed ID: 34597670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New directions in oncology nursing care: focus on gefitinib in patients with lung cancer.
    Pizzo B
    Clin J Oncol Nurs; 2004 Aug; 8(4):385-92. PubMed ID: 15354925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erlotinib: a new therapeutic approach for non-small cell lung cancer.
    Bonomi P
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1395-401. PubMed ID: 12882624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
    Maemondo M; Inoue A; Kobayashi K; Sugawara S; Oizumi S; Isobe H; Gemma A; Harada M; Yoshizawa H; Kinoshita I; Fujita Y; Okinaga S; Hirano H; Yoshimori K; Harada T; Ogura T; Ando M; Miyazawa H; Tanaka T; Saijo Y; Hagiwara K; Morita S; Nukiwa T;
    N Engl J Med; 2010 Jun; 362(25):2380-8. PubMed ID: 20573926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
    Blackledge G; Averbuch S
    Br J Cancer; 2004 Feb; 90(3):566-72. PubMed ID: 14760365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.
    Ihle NT; Paine-Murrieta G; Berggren MI; Baker A; Tate WR; Wipf P; Abraham RT; Kirkpatrick DL; Powis G
    Mol Cancer Ther; 2005 Sep; 4(9):1349-57. PubMed ID: 16170026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor.
    Zorzou MP; Stratigos A; Efstathiou E; Bamias A
    Acta Derm Venereol; 2004; 84(4):308-9. PubMed ID: 15339078
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.